Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
about
Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapyDiagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature reviewTherapeutic implications of autoantibodies in rheumatoid arthritisEarly biomarkers of joint damage in rheumatoid and psoriatic arthritisCandidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes.Anti-hnRNP B1 (RA33) autoantibodies are associated with the clinical phenotype in Russian patients with rheumatoid arthritis and systemic sclerosisMultinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in tAutoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodiesToward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor?Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis.Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides.Inhibition of Inflammation and Bone Erosion by RNA Interference-Mediated Silencing of Heterogeneous Nuclear RNP A2/B1 in Two Experimental Models of Rheumatoid Arthritis.Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays.Annexin A2 as a target endothelial cell membrane autoantigen in Behçet's diseaseTumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid jointA systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritisPretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.Enhanced neutrophil phagocytic capacity in rheumatoid arthritis related to the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptides.Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trialsPrediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope.Improved serological detection of rheumatoid arthritis: a highly antigenic mimotope of carbonic anhydrase III selected in a murine model by phage display.Can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes?Physical Characteristics of a Citrullinated Pro-Filaggrin Epitope Recognized by Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Sera.Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort.Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?Treating very early rheumatoid arthritisAssociation of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trialDetermination of specificity and sensitivity of anti-RA 33 in diagnosis of early rheumatoid arthritis.The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?HnRNP A1 is Involved in Deep Vein Thrombosis Patients with Behçet's DiseaseIdentification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritisAdvances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets.Urinary interleukin-6 as a predictor of radiographic progression in rheumatoid arthritis: A 3-year evaluation.Rheumatoid factors: clinical applications.Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients.A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis.
P2860
Q21195370-BCFC32B0-6F4D-4A27-B298-5B97EAC4216AQ24675281-FBDAFBFE-46AA-49DA-BAFE-89B74B99D776Q26744033-28EB99BB-6479-4668-89DC-2D95CF67D8CBQ28083506-ABCEBCE3-322C-4ACA-925E-B11738817105Q33417857-DE807100-A500-4FD0-8B82-35F2AC22BB55Q33634999-B1C2B119-54BC-44DC-B58B-303365D8166BQ33665938-16C0DCA4-046E-41C6-97F5-4BA063752114Q33673310-87016FE7-AA86-4D2C-B4AC-C21A89EA44EAQ33888275-C36BE868-E2E2-4A71-97EE-7F3875F7BED2Q33893960-1F4FD587-6EFD-48D4-B5DD-7414E56F19C9Q34110066-2D5EC54F-456E-4133-9703-AE54D343072CQ34244715-643A7629-8131-4793-A0E2-933091CF7B79Q34425604-3F030A7E-4DA8-445C-9459-EBBE2AC6A4F4Q34478119-A218FA68-91C5-489B-9E89-45A1B5BE7E17Q34652565-D2E56D91-74B7-4C21-8E80-1FCE9D44B424Q35035563-8E91C3EA-F7BB-4DFF-9998-3A5793CC597CQ35094171-FD35F32A-34BF-4F2A-AF2E-3C4B1B0E3901Q35207886-F6649FFB-416D-449E-83DF-BBEAEF2CFFFDQ35605424-9AB60C76-28CB-4573-93E1-692D658CEAF4Q35617658-9E2427F3-C5CA-4678-ABFB-FE6F895A49C7Q35677937-9F4CE181-4421-4DE7-8438-50C9139881F8Q35755442-3664B845-F222-40CC-A2E0-EF10B4CEA2F5Q35760017-32A7EECD-C21B-468C-8ECA-DA7636E62D5BQ35825343-94544EF3-932B-4142-97A8-3208438A8C84Q35840850-926CC504-99CC-4E55-8478-BFAFFC677649Q36230539-4FC6A00F-8244-49D1-A9D1-71F5D4597324Q36329372-1FEE1FC7-E8EB-45AD-8628-3C03E9BC6180Q36486374-19CA8935-0581-4FD4-93B9-14FAE804BE3EQ36596130-619CFF89-7008-4EEE-A95B-C3B000F962E7Q36657901-A5319B0A-042B-4EF3-A447-10D521A98CDFQ36779918-5682E254-1774-4D75-9166-8A6A03249208Q36790324-2018CD0E-AC18-462B-8349-1B122BE1556BQ36870010-3ED062F1-648D-47B0-A96A-7AE26BC871FDQ36968011-DDB7B5A6-A69C-4AE2-B2C7-8FB4C42845F9Q37131055-D5B7CE72-3F1E-41AE-AAD8-BD2ECB4C904CQ37330396-2B58AD61-64A3-4759-AB7D-F6BBBF2EDD4CQ37353700-93A2DE9A-C13E-445E-8C1A-A77F9BCBD1B2Q37530709-ECFE4813-5C00-4CFF-9907-DB98395CD742Q37546519-356F697F-E50C-43D3-9672-C1623DCF3222Q37587406-6D8D50E0-78EF-4D40-A1B0-001FFECBBB9E
P2860
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
@ast
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
@en
type
label
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
@ast
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
@en
prefLabel
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
@ast
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.
@en
P2093
Machold KP
P2860
P304
P356
10.1136/ARD.2005.035691
P407
P577
2005-05-05T00:00:00Z